Analysing compliance with Calcium and Vitamin D supplementations in patients receiving bone resorptive agents.

Not Applicable

Active, not recruiting

• Conditions: cancer; Multiple Myeloma; prostate cancer; bone metastasis; Breast Cancer; Other cancers with bone metastasis; Cancer - Bone; Cancer - Breast; Cancer - Prostate; Cancer - Myeloma

• Registration Number: ACTRN12621000383864
• Lead Sponsor: Icon Cancer Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-07
• Last Update Posted: 5 February 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

Patients over the age of 18 treated at Icon Cancer Centre sites where Denosumab, Pamidronate or Zoledronic acid has been prescribed between August 2021 and recruitment period of 24 months in total or until goal participant numbers have been reached.

Exclusion Criteria

Patients with hyperglycemia of malignancy;
Patients with history of osteoporosis.
Patients participating in other clinical trials

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- To identify rates of compliance to prescribed calcium and vitamin D supplements. This will be ascertained by completion of survey to be carried out by patients. Survey was developed using prescriber-requested questions and the Morisky Medication Adherence Scale (MMAS-8). [ Cumulative data will be assessed after all the participants have completed questionnaires and additional data has been completed ];To identify barriers to compliance in order to improve on patient care -This will be ascertained by survey responses by patients. [ Cumulative data will be assessed after all the participants have completed questionnaires and additional data has been completed ]

Secondary Outcome Measures

Name	Time	Method
not applicable.[ not applicable ]